



# Embracing the challenges of neonatal and paediatric pulmonary hypertension

Dunbar Ivy <sup>1</sup>, Erika B. Rosenzweig<sup>2</sup>, Steven H. Abman <sup>3</sup>, Maurice Beghetti<sup>4</sup>, Damien Bonnet <sup>5</sup>, Johannes Menno Douwes<sup>6</sup>, Alessandra Manes<sup>7</sup> and Rolf M.F. Berger <sup>8</sup>

<sup>1</sup>Pediatric Cardiology, University of Colorado School of Medicine, and Children's Hospital Colorado, Aurora, CO, USA. <sup>2</sup>Department of Pediatrics, Maria Fareri Children's Hospital at WMC Health and New York Medical College of Touro University, Valhalla, NY, USA. <sup>3</sup>Department of Pediatrics, University of Colorado School of Medicine, and Children's Hospital Colorado, Aurora, CO, USA. <sup>4</sup>Paediatric Cardiology Unit, Department of Paediatrics, Gynecology and Obstetrics, Geneva University Hospital, University of Geneva, Geneva, Switzerland. <sup>5</sup>Centre de Référence Malformations Cardiaques Congénitales Complexes, M3C, Necker Hospital for Sick Children, Assistance Publique des Hôpitaux de Paris, Paediatric Cardiology, Paris, France. <sup>6</sup>Center for Congenital Heart Diseases, Paediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. <sup>7</sup>Cardiology Unit IRCCS, S. Orsola University Hospital, Bologna, Italy. <sup>8</sup>Center for Congenital Heart Diseases, Paediatric and Congenital Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Corresponding author: Erika B. Rosenzweig ([Erika.BermanRosenzweig@wmchealth.org](mailto:Erika.BermanRosenzweig@wmchealth.org))



Shareable abstract (@ERSpublications)

This article discusses recent advances, ongoing challenges and distinct approaches for caring for infants and children with pulmonary arterial hypertension, as presented by the paediatric task force of the 7th World Symposium on Pulmonary Hypertension. <https://bit.ly/4bSg66C>

Cite this article as: Ivy D, Rosenzweig EB, Abman SH, et al. Embracing the challenges of neonatal and paediatric pulmonary hypertension. *Eur Respir J* 2024; 64: 2401345 [DOI: 10.1183/13993003.01345-2024].

This extracted version can be shared freely online.

Copyright ©The authors 2024.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

This article has an editorial commentary:  
<https://doi.org/10.1183/13993003.01222-2024>

Received: 11 July 2024  
Accepted: 11 July 2024

## Abstract

Paediatric pulmonary arterial hypertension (PAH) shares common features with adult disease, but is associated with several additional disorders and challenges that require unique approaches. This article discusses recent advances, ongoing challenges and distinct approaches for caring for infants and children with PAH, as presented by the paediatric task force of the 7th World Symposium on Pulmonary Hypertension. We provide updates on diagnosing, classifying, risk-stratifying and treating paediatric pulmonary hypertension (PH) and identify critical knowledge gaps. An updated risk stratification tool and treatment algorithm is provided, now also including strategies for patients with associated cardiopulmonary conditions. Treatment of paediatric PH continues to be hindered by the lack of randomised controlled clinical trials. The challenging management of children failing targeted PAH therapy is discussed, including balloon atrial septostomy, lung transplantation and pulmonary-to-systemic shunt (Potts). A novel strategy using a multimodal approach for the management of PAH associated with congenital heart diseases with borderline pulmonary vascular resistance is included. Advances in diagnosing neonatal PH, especially signs and interpretation of PH by echocardiography, are highlighted. A team approach to the rapidly changing physiology of neonatal PH is emphasised. Challenges in drug approval are discussed, particularly the challenges of designing accurate paediatric clinical trials with age-appropriate end-points and adequate enrolment.

